BRAF and metastatic melanoma: Clinical studies indicated that a combination of dabrafenib and trametinib, compared with dabrafenib alone, improved the 16% overall response rate in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations [101,108].